Sandro Pignata, Vladyslav Sukhin, N. Colombo, J. Korach, Takashi Matsumoto, Susan Lalondrelle, J. Vizkeleti, Leslie M Randall, Vanessa Samouelian, Pamela Salman, Angélica Nogueira-Rodrigues, Ali Ayhan, Juan F Cueva, Yong Man Kim, E. Petru, Karin Yamada, Kan Li, Elizabeth Szamreta, Allison Martin Nguyen, Domenica Lorusso
{"title":"285 在高风险局部晚期宫颈癌患者中开展的 3 期随机、双盲、安慰剂对照 ENGOT-Cx11/GOG 3047/KEYNOTE-A18 研究的患者报告结果","authors":"Sandro Pignata, Vladyslav Sukhin, N. Colombo, J. Korach, Takashi Matsumoto, Susan Lalondrelle, J. Vizkeleti, Leslie M Randall, Vanessa Samouelian, Pamela Salman, Angélica Nogueira-Rodrigues, Ali Ayhan, Juan F Cueva, Yong Man Kim, E. Petru, Karin Yamada, Kan Li, Elizabeth Szamreta, Allison Martin Nguyen, Domenica Lorusso","doi":"10.1136/ijgc-2024-esgo.53","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"32 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"285 Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer\",\"authors\":\"Sandro Pignata, Vladyslav Sukhin, N. Colombo, J. Korach, Takashi Matsumoto, Susan Lalondrelle, J. Vizkeleti, Leslie M Randall, Vanessa Samouelian, Pamela Salman, Angélica Nogueira-Rodrigues, Ali Ayhan, Juan F Cueva, Yong Man Kim, E. Petru, Karin Yamada, Kan Li, Elizabeth Szamreta, Allison Martin Nguyen, Domenica Lorusso\",\"doi\":\"10.1136/ijgc-2024-esgo.53\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":517822,\"journal\":{\"name\":\"Oral Sessions\",\"volume\":\"32 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oral Sessions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ijgc-2024-esgo.53\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.53","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
285 Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-Cx11/GOG 3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in patients with high-risk locally advanced cervical cancer